Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes

Drug Metabolism and Disposition

Volumn 35, Issue 9, 2007, Pages 1687-1693

  Aitken, Alison E ^a   Morgan, Edward T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C; CYTOCHROME P450 3A4; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFLAMMATION; LIVER CELL; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HEPATOCYTES; HUMANS; INDICATORS AND REAGENTS; INFLAMMATION; OXIDOREDUCTASES, N-DEMETHYLATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 34548090571     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015511     Document Type: Article

References (40)

1. Abdel-Razzak Z, Corcos L, Fautrel A, Campion JP, and Guillouzo A (1994) Transforming growth factor-β1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture. Mol Pharmacol 46:1100-1110.
2. Abdel-Razzak Z, Corcos L, Fautrel A, and Guillouzo A (1995) Interleukin-1β antagonizes phenobarbital induction of several major cytochromes P450 in adult rat hepatocytes in primary culture. FEBS Lett 366:159-164.
3. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, and Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707-715.
4. Aitken AE, Richardson TA, and Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149.
5. Ashino T, Oguro T, Shioda S, Horai R, Asano M, Sekikawa K, Iwakura Y, Numazawa S, and Yoshida T (2004) Involvement of interleukin-6 and tumor necrosis factor α in CYP3A11 and 2C29 down-regulation by bacillus Calmette-Guérin and lipopolysaccharide in mouse liver. Drug Metab Dispos 32:707-714.
6. Assenat E, Gerbal-Chaloin S, Larrey D, Saric J, Fabre JM, Maurel P, Vilarem MJ, and Pascussi JM (2004) Interleukin 1β inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology 40:951-960.
7. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, and Feingold KR (2002) Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophys Res Commun 293:145-149.
8. Carcillo JA, Doughty L, Kofos D, Frye RF, Kaplan SS, Sasser H, and Burckart GJ (2003) Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 29:980-984.
9. Cheng PY, Wang M, and Morgan ET (2003) Rapid transcriptional suppression of rat cytochrome P450 genes by endotoxin treatment and its inhibition by curcumin. J Pharmacol Exp Ther 307:1205-1212.
10. Donato MT, Gomez-Lechon MJ, Jover R, Nakamura T, and Castell JV (1998) Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J Pharmacol Exp Ther 284:760-767.
11. Donato MT, Guillén MI, Jover R, Castell JV, and Gomez-Lechon MJ (1997) Nitric oxide-mediated inhibition of cytochrome P450 by interferon-γ in human hepatocytes. J Pharmacol Exp Ther 281:484-490.
12. Frye RF, Schneider VM, Frye CS, and Feldman AM (2002) Plasma levels of TNF-α and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 8:315-319.
13. Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, and Branch RA (2006) Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 80:235-245.
14. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, and de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306.
15. Goldstein JA and de Morais SM (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
16. Guillén MI, Donato MT, Jover R, Castell JV, Fabra R, Trullenque R, and Gomez-Lechon MJ (1998) Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. J Pharmacol Exp Ther 285:127-134.
17. Iber H and Morgan ET (1998) Regulation of hepatic cytochrome P450 2C11 by transforming growth factor-β, hepatocyte growth factor, and interleukin-11. Drug Metab Dispos 26:1042-1044.
18. Jover R, Bort R, Gomez-Lechon MJ, and Castell JV (2002) Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 16:1799-1801.
19. Kraemer MJ, Furukawa CT, Koup JR, Shapiro GG, Pierson WE, and Bierman CW (1982) Altered theophylline clearance during an influenza B outbreak. Pediatrics 69:476-480.
20. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
21. Läpple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, Eichelbaum M, and Kivisto KT (2003) Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 13:565-575.
22. T) method. Methods 25:402-408.
23. Martinez-Jiménez CP, Gomez-Lechon MJ, Castell JV, and Jover R (2005) Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein). Mol Pharmacol 67:2088-2101.
24. Morgan ET (1997) Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29:1129-1188.
25. Muntane-Relat J, Ourlin JC, Domergue J, and Maurel P (1995) Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22:1143-1153.
26. Nishimura M, Yoshitsugu H, Naito S, and Hiraoka I (2002) Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 122:339-361.
27. Renton KW (2004) Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5:235-243.
28. Richardson TA and Morgan ET (2005) Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice. J Pharmacol Exp Ther 314:703-709.
29. Rivory LP, Slaviero KA, and Clarke SJ (2002) Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87:277-280.
30. Rodríguez-Antona C, Bort R, Jover R, Tindberg N, Ingelman-Sundberg M, Gomez-Lechon MJ, and Castell JV (2003) Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 γ. Mol Pharmacol 63:1180-1189.
31. Rodríguez-Antona C, Jover R, Gomez-Lechon MJ, and Castell JV (2000) Quantitative RT-PCR measurement of human cytochrome P-450s: application to drug induction studies. Arch Biochem Biophys 376:109-116.
32. Schuetz EG (2004) Lessons from the CYP3A4 promoter. Mol Pharmacol 65:279-281.
33. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
34. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, and Jover R (2000) Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 32:49-55.
35. Strom SC, Pisarov LA, Dorko K, Thompson MT, Schuetz JD, and Schuetz EG (1996) Use of human hepatocytes to study P450 gene induction. Methods Enzymol 272:388-401.
36. Sunman JA, Hawke RL, LeCluyse EL, and Kashuba AD (2004) Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 32:359-363.
37. Tapner M, Liddle C, Goodwin B, George J, and Farrell GC (1996) Interferon γ down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes. Hepatology 24:367-373.
38. Tian Y, Ke S, Denison MS, Rabson AB, and Gallo MA (1999) Ah receptor and NF-κB interactions, a potential mechanism for dioxin toxicity. J Biol Chem 274:510-515.
39. Totah RA and Rettie AE (2005) Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341-352.
40. Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, Thummel KE, et al. (2006) Mutual repression between steroid and xenobiotic receptor and NF-κB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 116:2280-2289.